Skip to content

A Prospective Randomized Controlled Study of Endoscopic Longitudinal Incision Combined with Local Triamcinolone Injection for The Sequential Treatment of Complex Esophageal Stricture

A Prospective Randomized Controlled Study of Endoscopic Longitudinal Incision Combined with Local Triamcinolone Injection for The Sequential Treatment of Complex Esophageal Stricture

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081526
Enrollment
Unknown
Registered
2024-03-04
Start date
2024-03-10
Completion date
Unknown
Last updated
2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex esophageal stricture

Interventions

Experimental group:Sequential treatment with endoscopic incision combine with local triamcinolone acetonide injection
Control group:Sequential treatment with endoscopic dilation combine with local triamcinolone acetonide injection

Sponsors

Air Force Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meet the limited CES inclusion criteria of this project (esophageal stenosis with a long segment between 2 and 5cm, after traditional dilatation3) Recurrent esophageal sricture at second or more times); (2) Willing to receive sequential therapy with EBD or EI combined with triamcinolone; (3) Patients whose general condition can tolerate general anesthesia and endoscopic treatment; (4) Patients can nor eat semi-liquid and solid food (Stooler score =3); (5) Those who are willing to participate in the clinical trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Malignant esophageal stricture or external pressure stricture; (2) Esophageal stricture with esophageal fistula or acute active inflammation (including infectious and non-infectious esophagitis); (3) Patients with triamcinolone hypersensitivity; (4) Severe abnormal coagulation function, cardiopulmonary diseases, etc., can not tolerate endoscopic treatment under general anesthesia; (5) Patients with severe diseases of other organs with an expected survival time of less than 6 months; (6) Patients with poor compliance and unable to follow the study design for sequential treatment; (7) Other situations that cannot cooperate with the completion of clinical trials.

Design outcomes

Primary

MeasureTime frame
Rate of dysphagia-free;

Secondary

MeasureTime frame
Number of treatments;Treatment interval;Medium and long term efficacy;The rate of significant efficacy;Restricture rate;Quality of life;Nutritional status;Length of stay;

Countries

China

Contacts

Public ContactShoubin Ning

Air Force Medical Center

ning-shoubin@163.com+86 156 1116 5923

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026